Document Detail


Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.
MedLine Citation:
PMID:  8307444     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The extent of duodenal bacterial overgrowth during the pronounced inhibition of acid secretion that occurs with omeprazole treatment is unknown. The bacterial content of duodenal juice of patients treated with omeprazole was therefore examined in a controlled prospective study. Duodenal juice was obtained under sterile conditions during diagnostic upper endoscopy. Aspirates were plated quantitatively for anaerobic and aerobic organisms. Twenty five outpatients with peptic ulcer disease were investigated after a 5.7 (0.5) weeks (mean (SEM)) treatment course with 20 mg (nine patients) or 40 mg (16 patients). The control group consisted of 15 outpatients referred for diagnostic endoscopy without prior antisecretory treatment. No patient in the control group had duodenal bacterial overgrowth. In the omeprazole group bacterial overgrowth (> or = 10(5) cfu/ml) was found in 14 (56%) patients (p = 0.0003). The number of bacteria (log10) in duodenal juice in patients treated with omeprazole was distinctly higher (median 5.7; range < 2-8.7) when compared with the control group (median < 2; range < 2-5.0; p = 0.0004). As well as orally derived bacteria, faecal type bacteria were found in seven of 14 and anaerobic bacteria in three of 14 patients. Bacterial overgrowth was similar with the two doses of omeprazole. These results indicate that duodenal bacterial overgrowth of both oral and faecal type bacteria occurs often in ambulatory patients treated with omeprazole. Further studies are needed to determine the clinical significance of these findings, particularly in high risk groups during long term treatment with omeprazole.
Authors:
M Fried; H Siegrist; R Frei; F Froehlich; P Duroux; J Thorens; A Blum; J Bille; J J Gonvers; K Gyr
Related Documents :
2897784 - Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative ...
8329794 - Oral agents in the management of urticaria: patient perception of effectiveness and lev...
3898834 - Sucralfate and cimetidine as single agents and in combination for treatment of active d...
7863254 - Nizatidine as maintenance treatment of duodenal ulcer. clinical results.
22147664 - Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizu...
6456414 - Treatment of intractable rheumatoid arthritis with total lymphoid irradiation.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Gut     Volume:  35     ISSN:  0017-5749     ISO Abbreviation:  Gut     Publication Date:  1994 Jan 
Date Detail:
Created Date:  1994-03-15     Completed Date:  1994-03-15     Revised Date:  2012-05-09    
Medline Journal Info:
Nlm Unique ID:  2985108R     Medline TA:  Gut     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  23-6     Citation Subset:  AIM; IM    
Affiliation:
Department of Gastroenterology, University Hospital, Lausanne, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Bacteria / drug effects*,  growth & development,  isolation & purification
Duodenum / microbiology*
Female
Humans
Intestinal Secretions / microbiology*
Male
Middle Aged
Omeprazole / pharmacology*
Peptic Ulcer / microbiology*
Prospective Studies
Streptococcus / isolation & purification
Chemical
Reg. No./Substance:
73590-58-6/Omeprazole
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evidence for the essential role of Helicobacter pylori in gastric ulcer disease.
Next Document:  Effect of the quaternary ammonium compound trospium chloride on 24 hour jejunal motility in healthy ...